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Abstract
Inherited myopathies are a heterogeneous group of disabling disorders with still barely understood pathological
mechanisms. Around 40% of afflicted patients remain without a molecular diagnosis after exclusion of known genes. The
advent of high-throughput sequencing has opened avenues to the discovery of new implicated genes, but a working list of
prioritized candidate genes is necessary to deal with the complexity of analyzing large-scale sequencing data. Here we used
an integrative data mining strategy to analyze the genetic network linked to myopathies, derive specific signatures for
inherited myopathy and related disorders, and identify and rank candidate genes for these groups. Training sets of genes
were selected after literature review and used in Manteia, a public web-based data mining system, to extract disease group
signatures in the form of enriched descriptor terms, which include functional annotation, human and mouse phenotypes, as
well as biological pathways and protein interactions. These specific signatures were then used as an input to mine and rank
candidate genes, followed by filtration against skeletal muscle expression and association with known diseases. Signatures
and identified candidate genes highlight both potential common pathological mechanisms and allelic disease groups.
Recent discoveries of gene associations to diseases, like B3GALNT2, GMPPB and B3GNT1 to congenital muscular dystrophies,
were prioritized in the ranked lists, suggesting a posteriori validation of our approach and predictions. We show an example
of how the ranked lists can be used to help analyze high-throughput sequencing data to identify candidate genes, and
highlight the best candidate genes matching genomic regions linked to myopathies without known causative genes. This
strategy can be automatized to generate fresh candidate gene lists, which help cope with database annotation updates as
new knowledge is incorporated.
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Background
A large number of disorders affecting skeletal muscle have a
genetic basis, with multiple modes of inheritance. They are
classified based on phenotype and histopathological features into
several groups, which include muscular dystrophies, congenital
myopathies and myotonic syndromes, among others (Table 1) [1].
Muscular dystrophies and congenital muscular dystrophies, for
example, are characterized by dystrophic changes on muscle
biopsy, as opposed to congenital myopathies, which have non-
dystrophic peculiar histopathologic findings [2–5]. Despite being
rare, most inherited myopathies impose a heavy burden on the life
of affected persons, and have a strong impact on the health care
system. The identification of the causative gene and mutations is
often a pre-requisite for genetic counseling and potentially
prenatal diagnosis, improved disease care, and access to more
specific therapies or inclusion in clinical trials. A lot of advances
have been made in the last few decades on the molecular bases of
inherited myopathies, which included the discovery of about 130
genes associated with different disorders [1]. Still, it is estimated
that around 40% of patients afflicted with myopathies remain
without a molecular diagnosis, supporting the implication of
additional genes [6,7]. Further identification of these genes is the
focus of a tremendous research effort at present, and will help
understand pathological mechanisms and defining novel drug
targets.
Next-generation sequencing (NGS) is a relatively new technol-
ogy that enables massive parallel sequencing of a huge number of
bases. It has revolutionized molecular diagnosis and genetic
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research, as it represents a cost-effective way of testing several
genes at once in disorders with genetic heterogeneity, such as
myopathies [8–10]. Moreover, exome sequencing (ES) or genome
sequencing (GS) aid in the discovery of new genes associated with
various diseases [11,12]. There has recently been a surge in
publications that use NGS to discover new genes associated with
diseases, including myopathies [13–20].
The biggest challenge of NGS is to cope with the complexity of
analyzing the massive amount of variants generated by the
approach. Indeed, comparing two unrelated individuals may lead
to about 3 million matching variants in their genomes or about
20,000 in their exomes, but only one of these variants can cause a
monogenic disease. The resolution of this issue demands good
filtering pipelines to exclude common or meaningless variants,
based on the biochemical function of genome location as studied
through the ENCODE project [21], and on relationships between
human variations and phenotype as in ClinVar and in locus
specific databases [22,23]. In addition, ranking systems can help
prioritize validation of the most promising variants. It makes sense
to focus on genes presumably implicated in the disease process via
functional, structural or phenotypical links with known genes. One
of the approaches to collect and compare these data is via in silico
analysis using a multitude of open-access knowledge information
sources. This approach has been recently done successfully for
some disorders but not yet for myopathies [24,25]. Lists of
candidate genes thus generated can be ranked and used to
prioritize variants resulting from NGS analysis.
Here, we propose ranked lists of candidate genes for individ-
ualized groups of inherited myopathies and related diseases that
were obtained via data mining of online information databases.
These lists can be coupled to NGS analyses pipelines to help filter
and prioritize variants aiming at the discovery of novel genes. We
also put forward a number of genetic and functional insights taken
from the generation of signatures for such disease groups to suggest
common pathological pathways between them that can be subject
of further scrutiny.
Methods
Classification of myopathy genes into 9 overlapping
disease groups
The disease groups and associated known genes were based on a
modified version of the Gene Table of Neuromuscular Disorders
(GTNMD) [26]. We selected the following disease groups, which
are primarily related to skeletal muscle pathology: Muscular
Dystrophies, Congenital Muscular Dystrophies, Congenital My-
opathies, Myotonic Syndromes, Ion Channel Muscle Diseases,
Metabolic Myopathies, and Congenital Myasthenic Syndromes.
To cope with an ill-defined classification of ‘‘Other Myopathies’’
in the GTNMD, we decided to cluster genes from this group into
two new disease groups, Myofibrillar Myopathies and Vacuolar
Myopathies. A literature search was performed to find recently
published genes not yet listed in the Gene Table version that was
used in our present study, which resulted in the addition of the
following genes: VMA21 [16] and EPG5 [14] to the Vacuolar
Myopathies group; TRAPPC11 [13] and TNPO3 [19,27] to the
Muscular Dystrophies group; and STIM1 [20], CCDC78 [15] and
KLHL40 [17] to the Congenital Myopathies group.
The disease groups have some degree of overlap due to
phenotypic heterogeneity of certain genes. For example, SEPN1 is
Table 1. Breakdown of disease groups and known associated genes.
Disease group Main diseases Associated genes
Muscular dystrophies Duchenne and Becker muscular
dystrophies, Emery-Dreifuss
muscular dystrophy, Limb-girdle
muscular dystrophies
ANO5, CAPN3, CAV3, DAG1, DES, DMD, DNAJB6, DPM3, DUX4, DYSF,
EMD, FHL1, FKRP, FKTN, LMNA, MYOT, PABPN1, PLEC, POMGNT1,
POMT1, POMT2, PTRF, SGCA, SGCB, SGCD, SGCG, SYNE1, SYNE2,
TCAP, TMEM43, TNPO3, TRAPPC11, TRIM32, TTN
Congenital muscular
dystrophies
Merosin-deficient CMD,
Dystroglycanopathies, Ulrich and
Bethlem myopathies
CHKB, COL6A1, COL6A2, COL6A3, DNM2, DPM2, FHL1, FKRP, FKTN,
GTDC2, ISPD, ITGA7, LAMA2, LARGE, LMNA, POMGNT1, POMT1,
POMT2, SEPN1, TCAP
Congenital myopathies Centronuclear myopathy, Nemaline
myopathy, Central core disease
ACTA1, BIN1, CCDC78, CFL2, CNTN1, DNM2, KBTBD13, KLHL40,
MEGF10, MTM1, MTMR14, MYH2, MYH7, NEB, RYR1, SEPN1, STIM1,
TNNT1, TPM2, TPM3, TRIM32, TTN
Metabolic myopathies Glycogen storage diseases (Pompe,
McArdle), Lipid storage diseases
(CPTII deficiency)
ACADVL, AGL, CPT2, ENO3, GAA, GBE1, GYG1, GYS1, LDHA, LPIN1,
PFKM, PGAM2, PGK1, PGM1, PHKA1, PNPLA2, PYGM, SLC22A5,
SLC25A20
Congenital myastenic
syndromes
Acetylcholine receptor deficiency,
Choline acetyl transferase deficiency,
Escobar syndrome
AGRN, CHAT, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, COLQ,
DOK7, DPAGT1, GFPT1, LAMB2, MUSK, RAPSN, SCN4A
Myotonic syndromes Myotonic dystrophy type 1 (Steinert
disease), Schwartz-Jampel disease
ATP2A1, CAV3, CNBP, DMPK, HSPG2
Ion channel muscle diseases Myotonia congenita, Hyperkalemic
periodic paralysis, Paramyotonia
congenita
CACNA1S, CLCN1, SCN4A
Vacuolar myopathies Myopathy with excessive autophagia,
Danon disease, Inclusion body
myopathy with Paget disease of bone
and frontotemporal dementia
EPG5, GNE, LAMP2, VCP, VMA21
Myofibrillar myopathies Alpha-B-crystallin related myofibrillar
myopathy, Desmin related myofibrillar
myopathy
BAG3, CRYAB, DES, FLNC, LDB3, MYOT, SEPN1
doi:10.1371/journal.pone.0110888.t001
Data Mining of Candidate Genes for Myopathies
PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e110888
implicated in multi-minicore disease (a congenital myopathy), and
in rigid-spine muscular dystrophy (a congenital muscular dystro-
phy); CAV3 both causes limb-girdle muscular dystrophy 1C (a
muscular dystrophy), and rippling muscle disease (a myotonic
syndrome). The largest overlap is found between Muscular
Dystrophies and Congenital Muscular Dystrophies, with 8 genes
out of 34 muscular dystrophy-associated genes also found among
20 congenital muscular dystrophy-associated genes.
GTNMD’s disease group "Distal Myopathies" was not included
as a separate class in this work due to the lack of a gene uniquely
associated with it - all genes were also found in other disease
groups. Non-myopathy disease groups, such as ataxias, neuropa-
thies, and motor neuron diseases, were also not included, as well as
genes that, although listed in the GTNMD under included disease
groups, do not lead to a skeletal muscle phenotype. This was the
case of MYBPC3, implicated in cardiomyopathies, removed from
the Congenital Myopathies group; PRKAG2, which causes a
glycogen storage disease of the heart, not included in the
Metabolic Myopathies group; and genes excluded from the Ion
Channel Muscle Diseases group because they lead to various
ataxia and cardiac arrhythmia syndromes, while not resulting in
periodic muscle paralysis. The full list of genes and disease groups
used in this work can be found in Table 1.
Data-mining from online databases to address complex
biological questions
We used the data mining system Manteia [28], a public
resource available online (manteia.igbmc.fr) that retrieves and
combines data from freely available online data sources such as
Ensembl, Reactome, OMIM, NCBI, Human Phenotype Ontology
(HPO), Gene Ontology (GO), Mouse Genome Informatics, and
InterPro. Manteia makes it possible to address complex biological
questions by running several queries at the same time to mine and
statistically analyze gene sets to highlight their annotation
specificities compared to the rest of the genome. This study was
conducted with Manteia version 2 with data downloaded in June
2013 from the different databases used in the system.
Using Manteia’s orthology module, we analyzed human gene
sets and their mouse orthologs to find an enrichment on
statistically significant terms within several annotation categories,
including Gene Ontology (GO), Human Phenotype Ontology
(HPO), Mammalian Phenotype Ontology (MPO), pathways
(Reactome), protein motifs (Interpro) and interacting complexes
(Reactome). Gene length was not taken into account as there is no
clear enrichment of large genes mutated in myopathies; while
some large genes are indeed implicated (TTN, NEB), smaller
genes were found to accumulate mutations along their sequence
(e.g. ACTA1). Manteia calculates the enrichment of each term in
the gene set compared to all genes in the genome, and sorts the
terms according to individual statistical significances.
The list of specific terms for each data set can then be used to
screen the genome looking for genes that have similar properties.
This is achieved using a query builder, which outputs a list of
candidate genes ranked according to their similarity with the data
set annotation signature and the weight given for each term.
Extraction of specific signatures for each disease group
based on known genes
Statistical analysis for human genes in each disease group was
individually performed for Gene Ontology (GO) terms, Human
Phenotype Ontology (HPO) terms, pathways, complexes and
protein motifs. Mouse orthologs were additionally used to get
statistical breakdowns of Mammalian Phenotype Ontology (MPO)
terms.
Signatures were represented by a weighted combination of GO
terms, HPO terms, MPO terms, and what were collectively called
"Interactions Annotation" (IA) terms - pathways and protein
complexes descriptors from Reactome and descriptors of protein
motifs from InterPro. For each disease group, terms were chosen
from the various domains in order to obtain a signature of the
disease group. We used the following criteria to select GO terms,
HPO terms and MPO terms for each group: 1) significance p-
value less than 0.05 (corrected using the Benjamini-Hochberg false
discovery rate (FDR) procedure); 2) occurrence in the disease
group gene set greater than 1; 3) occurrence in the genome ,800;
4) GO level (or HPO level or MPO level) .2.
The FDR-BH correction of the p-value was chosen because it
reduced the large size of the list of resulting terms while not being
as stringent as the Bonferroni correction. Terms with only one
occurrence in the gene set were deemed not representative of the
set. Criteria 3 and 4 enrich for specificity and are closely associated
owing to less specific terms (higher ontology level) being associated
with a large number of genes; such general terms would not only
be unproductive in compounding a signature for a disease group,
but also could degrade the performance of a complex query.
For IA terms, the restriction on the occurrence of only one gene
in the set was dropped with the aim of improving the scores of new
genes related to protein function linked to single known myopathy
gene. Indeed, a large proportion of significant terms have only one
occurrence in any given disease group gene set. Finally, criteria 4
does not apply to Interpro and Reactome data, which are not
structured in defined hierarchies as gene and phenotype ontolo-
gies.
Ranking formula based on weighted scores of signature
terms
After experimenting with different signature definitions, we
decided to define a signature as having an equal contribution of
GO terms, phenotype terms (HPO and MPO terms) and IA terms
(Figure 1), so as not to a priori give more importance to any term
set. A signature with a stronger component of phenotype terms, for
example, yields a list of purported candidates strongly biased to
genes implicated in known diseases or for which mouse models
have been extensively phenotyped. Likewise, if GO terms are the
main component of the signature, genes with functional links are
preferentially ranked. Finally, IA terms boost the interactome of
the known genes to the top of the ranked lists.
Thus, in our approach, for each disease group, the weight of
individual terms was calculated so that the added weights of all
GO terms was the same as the total PO score (added HPO terms
weights combined with added MPO terms weights) and as the
added weights of all IA terms, which was arbitrarily set as 1000.
In the GO domain, we defined strata of term weights with
percentile cutoffs so that terms with a higher significance would
respond for a larger share of the total GO score. The top 20% of
terms (p80) contributed to 40% of the total GO score, a middle tier
comprising 40% of terms (p40-p80) contributed to an additional
40% of the total GO score, and the lower 40% of terms (p40)
provided 20% of the total GO score.
A similar approach was used to calculate individual weights for
HPO and MPO terms, with the exception that, as the total PO
score reflects the combination of equal shares of HPO and MPO
terms, the maximum score of either HPO terms or MPO terms
was set at 500.
The weight of each IA term, on the other hand, was the same
no matter its position on the corresponding list, and was simply
Data Mining of Candidate Genes for Myopathies
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calculated as 1000 divided by the number of significant IA terms
for each disease group. This approach helped mine all genes that
interacted with any single gene in the training set, provided
pathways and interactions were statistically significant.
While the choice of percentile cutoffs that define the strata of
weights was arbitrary, we observed that the modification of the
cutoffs did not result in substantially different ranked candidate
lists for each disease group, as long as the signature definition is the
same. All terms for every domain in each disease group, with their
corresponding calculated weights, can be found in Table S1.
Generation of ranked lists of candidate genes for each
disease group
Manteia’s query builder feature was used to filter genes in the
human genome that matched the signature defined for each
disease group. Queries combining terms that constitute the
signature were run to obtain a list of genes ranked by a score
represented by the sum of all matched term weights (Figure 1).
More specifically, a gene score results as the sum of a GO score
(sum of weights of the disease group’s signature GO terms that
match the gene’s GO terms), a PO score (sum of weights of
matching HPO and MPO terms), and an IA score (sum of weights
Figure 1. Integrated data mining workflow. A signature of a disease group, composed of weighted terms, is generated from statistical analyses
of genes already implicated in diseases of the group. Terms come from the three main annotation groups, GO (Gene Ontology), PO (Phenotype
Ontology, an aggregate of Human Phenotype Ontology and Mammalian Phenotype Ontology) and IA (Interactions Annotation), are mined using
Manteia and receive weights proportional to the their enrichment in the set of genes implicated in the disease group, as compared to the set of all
genes in the human genome. Weights are attributed to terms so that annotation groups contribute equally to the composition of the signature. The
signature of the disease group is then used to mine the genome for additional genes. Every gene in the genome receives a score equal to the sum of
weights of terms that describe the gene if they match terms that define the disease group signature, for a maximum possible score of 3000. Further
filtering steps mark genes that have low relative skeletal muscle expression or are annotated with known diseases.
doi:10.1371/journal.pone.0110888.g001
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of matching IA terms). The maximum total score a gene can
receive is thus 3000 (1000 for GO score+1000 for PO score+1000
for IA score). To deal with MPO terms applied to murine
orthologs, the predicted best human orthologs were selected using
Manteia’s ORTHO function after the ranking process. The
ranked lists for each of the 9 disease groups, including annotation
detailed in the next subsection, can be found in Table S2.
Additional filtering of ranked candidate genes using
expression data and association with human diseases
The ranked lists for each disease group include the known genes
of the group, which were used to create the signatures, genes
known to be associated with myopathies but implicated in other
disease groups, and genes that are not listed in any disease group
and thus represent potentially good candidate genes for myopa-
thies. Among those, additional filtering was performed using tissue
expression databases. Data from Illumina Body Map E-MAT513,
established from mRNA-Seq of 16 human tissues, was download-
ed for every gene, and genes with no expression in skeletal muscle
or with an expression in skeletal muscle that was less than a cutoff
of 10% of the maximum expression found in any other tissue were
excluded. The rationale behind this filtering is that if a gene is
expressed in a tissue other than skeletal muscle at a much higher
level, one expects such a gene to be implicated in disorders
primarily involving that tissue. The 10% cutoff was empirically
determined due to the fact that all genes already implicated in
myopathies have skeletal muscle expression levels above this
cutoff. To deal with missing expression data and eventual
heterogeneity in Illumina Body Map’s expression database, genes
ruled out by the 10% threshold and candidate genes within the
100 first positions in the rankings for each disease group were
double checked using expression data from the Genotype-Tissue
Expression Project (GTEx) [29].
For the Congenital Myasthenic Syndromes disease group,
which includes diseases primarily related to neuromuscular
junction protein defects, but also some peripheral nerve terminal
protein defects, we decided to disregard the muscle expression
filtering due to the fact that the implicated genes AGRN, CHAT,
and CHRNE do not have significant skeletal muscle expression
(they are instead expressed in the nerve terminal).
The lists of candidate genes after skeletal muscle expression
filtration was further annotated with Online Mendelian Inheri-
tance in Men (OMIM) data on existing human phenotype in the
form of well-characterized diseases or syndromes, in order to easily
identify genes biased by phenotype, such as SMN1, which results
in a phenotype very similar to many myopathies, characterized by
flaccid proximal limb weakness, but which gives rise instead to a
motor neuron disease; or biased by interactions, as occurs to a
number of carbohydrate metabolism genes that share common
pathways to metabolic myopathies but cause instead inborn errors
of metabolism without a muscle phenotype.
Results
Myopathy groups are clustered by gene ontology and
protein function
To identify novel candidate genes for myopathies, we estab-
lished an integrated data mining approach aiming first to extract
specific signatures for disease groups encompassing previously
implicated genes, and then to use these signatures to search for
additional matching genes in the human genome. As detailed in
Figure 1 and the methods section, this approach consists of a
weighted ranking of three main sets of data: gene ontology, human
and mouse phenotypes ontologies, and ‘‘interactions annotation’’
incorporating pathways and protein motifs and complexes.
To test this approach and better visualize signature composition
analysis, we first analyzed a training set that consisted in all
myopathy-associated genes using the data mining system Manteia
[28]. Figure 2 shows graphs with relationships between all known
genes of the nine chosen disease groups. In particular, the
combination of GO, PO and IA terms aggregate most genes that
are part of the same myopathy group for metabolic myopathies,
the congenital myasthenic syndromes, and the glycosylation
components of congenital muscular dystrophies (Figure 2A). Of
note, the gene GFPT1, which causes a congenital myasthenic
syndrome with tubular aggregates, has mainly relationships with
genes in the metabolic myopathy cluster, presumably because it
codes for an enzyme in the metabolism of glycoproteins. Another
large cluster in the graph encompasses the main genes implicated
in muscular dystrophies and congenital or myofibrillar myopa-
thies, without subdivision, suggesting a strong overlap in the
function of the related genes and potentially in the pathogenesis.
This approach can thus retrieve several phenotypic and pathologic
clusters. However, applying only the human phenotype ontology
analysis generates a single large, highly connected graph
(Figure 2B), even when the threshold for representing an edge in
the graph - number of matching HPO term between two genes - is
increased or decreased, or when HPO term hierarchy is taken into
account. This means that genes implicated in myopathies share a
common hierarchy of phenotype ontology terms, e.g. with most
genes annotated with muscle weakness or abnormal muscle
physiology related terms. While they do not help separate genes
into disease groups, HPO terms are important to help emerge
genes with phenotype annotation associated to skeletal muscle.
GO terms and IA terms, on the other hand, are responsible for the
final clustering. Different myopathy groups appear using only GO
terms (Figure 2C), while IA terms, even considering a lower
threshold of 5 terms shared between genes, create smaller clusters
of genes that interact closely by sharing the same pathways,
interactions complexes or motifs, such as constituents of collagen
VI, genes responsible for the assembly of nicotinic cholinergic
receptors, or conglomerated proteins involved with the sarcomere
(Figure 2D). Only the combination of the different GO, PO and
IA terms reaches the most precise clustering.
Characterization of disease groups via biological
processes annotation
We next aimed to extract specific signatures for each disease
group, classified based on the Gene Table of Neuromuscular
Disorders [1]. Statistical analysis of known genes was conducted
for each disease group.
GO terms include three types of ontologies: cellular components
indicate the localization of gene products; molecular function
refers to the normal roles of genes at the molecular level; and
biological processes describe the higher-order roles of genes from a
biological perspective. Four main general skeletal muscle-related
biological processes were extrapolated from the hierarchy of GO
terms: muscle contraction, calcium homeostasis, muscle develop-
ment, and muscle intracellular organization (Table 2). Analysis of
the breakdown of biological process-related GO terms that make
up the signatures of different disease groups reveals differences in
the implicated skeletal muscle processes and hints on other
important biological processes that do not primarily involve the
skeletal muscle.
Vacuolar myopathies and myofibrillar myopathies did not
receive in their signature GO terms associated with biological
processes, because the training set genes for these groups were
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annotated with heterogeneous terms that did not attain statistical
significance. Metabolic myopathies and congenital myasthenic
syndromes inferred biological processes were, as expected, not
primarily muscle related, but had mostly to do with glycogen
metabolism and neuromuscular junction, respectively. Congenital
muscular dystrophies, while having two GO terms associated with
muscle development, were also primarily annotated with non
muscle-specific biological processes, especially protein glycosyla-
Figure 2. Graph representation of relationships of known genes. All known genes for the different disease groups were concurrently
analyzed for matching terms in different ontologies. Nodes represent genes, and edges between two given nodes are depicted when the number of
terms shared by the two connected genes is greater than a certain threshold. Edge width is proportional to the number of terms shared between two
genes, and node size and color in a scale from green (lowest) to red (highest) is proportional to the number of associations of a gene in the graph.
Closely related genes appear clustered together, and hubs in the graph appear centrally located. A: graph for combined terms from Gene Ontology
(GO), Human Phenotype Ontology (HPO) and Interactions Annotation (IA), with a threshold of 30 matching terms. The cluster with a yellow
background includes genes implicated in metabolic myopathies, the one with a red background groups congenital muscular dystrophy genes, and
the cluster with a gray background represents genes associated with congenital myasthenic syndromes. B: graph for HPO terms with a threshold of
20 matching terms. C: graph for GO terms, with a threshold of 10 matching terms. Background colors correspond to clusters represented in A. D: IA
terms with a threshold of 5 matching terms. The gray background highlights a cluster with gene that code subunits of cholinergic receptors,
implicated in congenital myasthenic syndromes, the green one groups components of collagen VI, and the cluster with a blue background links
elements of the contractile apparatus.
doi:10.1371/journal.pone.0110888.g002
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tion. Myotonic myopathies and ion channel muscle diseases take
the larger contribution from calcium homeostasis-related terms.
Muscular dystrophies mainly involve muscle intracellular organi-
zation terms, but also receive some contribution from muscle
development and muscle contraction terms. Other important
biological processes for muscular dystrophies are associated with
heart muscle contraction and development. Finally, for congenital
myopathies, muscle development and calcium homeostasis seem to
be the most significant processes, but muscle contraction-related
terms also play a role, as well as processes not specific for skeletal
muscle, such as catabolism of nucleotides - these appear enriched
due to the association of DNM2 to the catabolism of GTP, as well
as MYH7 and TPM2 to the catabolism of ATP.
Training set genes appear at the top of the ranked lists of
the disease groups
We used the signature specific to each disease group to screen
the whole set of human genes and identify candidate genes for
myopathies. The breakdown of the gene score for these training
set genes shows that a similar contribution of the different term
domains can be consistently found throughout the various disease
groups. GO score, PO score and IA score respond for
approximately 30 to 45%, 40 to 55%, and 10 to 15% of the
gene score, respectively. Table 3 shows the ranked lists of known
genes for three disease groups (Congenital Myopathies, Muscular
Dystrophies and Metabolic Myopathies), along with each gene
score and breakdown of partial scores. Table S3 shows similar
additional data for all disease groups.
As expected, genes already known to be mutated in the various
disease groups, which were used as the training set to create the
mining signatures, appear at the top of the ranked lists of data
mining. Considering congenital myopathies, out of the 22 genes
chosen as the training set, 19 genes appeared in the data mining,
while genes CCDC78, KBTBD13, and KLHL40 did not have
annotation in the databases used at the time of this work. Thirteen
of these genes were ranked within the first 100 genes, a coverage of
13/19 (68.4%). The muscular dystrophy group had 31 out of 34
genes of its training set appearing in the data mining list, and of
these 23 were found within the first 100 ranked genes (79.3%). In
the metabolic myopathy disease group, all 19 genes of the training
set were ranked, and 18/19 were found within the top 100 genes
in the rank (94.7%). Outliers among the known genes are mostly
poorly annotated genes, and genes with no score are actually not
annotated at all (see discussion). Thus, the high ranking of most
previously implicated genes supports the signature choice having
adequately defined the disease group.
Proposed candidate genes after filtration
A number of candidate genes sharing disease group signatures
with known myopathy genes are barely expressed in skeletal
muscle or sometimes mutated in other diseases not affecting
skeletal muscle. We thus added filtering steps based on tissue
expression and known implication in diseases (see methods for
details). Table 4 shows the top 8 ranked genes for each disease
group after filtration on skeletal muscle expression and absence of
link with diseases in OMIM (Online Mendelian Inheritance in
Men, omim.org) database. Table S2 lists the full ranked list of
genes for each disease group without filtration, but annotated with
skeletal muscle expression and OMIM diseases, and can be linked
to NGS filtering pipelines to help prioritization of novel gene
discovery, as shown in the discussion. In the following paragraphs,
we discuss a few genes found as candidates in some of the disease
groups, to illustrate the connections between the integrated data
mining results and evidence from the literature.
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Candidate genes for muscular dystrophies display strong links
with muscle development, contraction and intracellular organiza-
tion, expected subcomponents of skeletal muscle-related biological
processes terms from the breakdown of GO terms. ITGB1 codes
for a subunit of ubiquitous fibronectin receptors and has a number
of suggested functions in different tissues. In skeletal muscle, it has
been proposed as a possible target for myostatin in mice myoblast
differentiation [30] and is also critical for the development of
neuromuscular junctions [31]. TMOD1 encodes for tropomodulin,
a protein that regulates tropomyosin and F-actin organization.
Knockout mice present with age-dependent sarcomere misalign-
ment and sarcoplasmic reticulum morphological defects [32].
MYL1 is involved with early differentiation of fast muscle cells [33]
and TNNI1 codes for the slow-twitch skeletal muscle isoform of
troponin I, which has yet to be associated with human diseases
even though the fast-twitch isoform is responsible for a subtype of
arthrogryposis and the cardiac isoform causes cardiomyopathy
syndromes.
Candidate genes for congenital myopathies have a significant
overlap with genes proposed for muscular dystrophies, for example
for TMOD1 and TNNI1. Among those with a high rank in
congenital myopathies are RYR3 and MYH1. RYR3 codes for a
ryanodine calcium release channel with a low Ca2+ sensitivity that
has a physiologic role in the excitation-contraction coupling of
neonatal skeletal muscles and is up regulated in steroid-associated
muscle damage [34], while MYH1 is one of the adult skeletal
muscle isoforms of myosin heavy chain that predominates in 2B
myofibers. RYR3 high ranking is boosted by a strong contribution
of calcium homeostasis terms, explaining why RYR3 received a
similarly high score in the Myotonic Syndromes and Ion Channel
Muscle Diseases groups, which also have a strong component of
calcium homeostasis terms. Also in the group of Ion Channel
Muscle Diseases, the gene CACNB1 encodes both the brain and
skeletal muscle isoforms of the calcium channel beta subunit, and
its loss in mouse is associated to a phenotype similar to that seen in
mice with mutations in the known genes CACNA1S or RYR1
[35].
Within congenital muscular dystrophies, the gene B3GALNT2,
ranked in the 97th place out of 4841 genes with annotation for this
group’s signature, was recently found to be associated with
hypoglycosylation of alpha-dystroglycan and a congenital muscu-
lar dystrophy phenotype in humans [18]. Two other genes,
GMPPB, ranked in 225th, and B3GNT1, ranked in 479th, were
also implicated in a form of congenital muscular dystrophy with
hypoglycosylation of alpha-dystroglycan and Walker-Warburg
disease, respectively [36,37]. These genes had not been used in
the training set of genes for congenital muscular dystrophies, and
have since been annotated in OMIM, but their high placement in
the ranking list validate the proposed data mining strategy and
subsequent filtering steps.
Candidate genes within genomic regions linked to
myopathies
A number of neuromuscular diseases have mapped loci awaiting
gene identification [1]. Matching the genomic positions of the top
100 candidate genes of each disease group with such mapped loci
reveals some interesting candidates (Table 5).
The gene XIRP1, matching the locus for hyalin body myopathy
and congenital muscular dystrophy with joint hyperlaxity, was
originally studied in relation to murine cardiac morphogenesis and
later shown to bind skeletal muscle actin in in vitro assays [38]. Its
product, the Xin protein, is skeletal muscle-specific and has
recently been put forward as a potentially useful biomarker of
muscle damage, which can be used to monitor disease progression
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Table 4. Top 8 ranked candidate genes for each disease group.
Muscular dystrophies
Rank Gene Name Score
33 ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes
MDF2, MSK12)
437
42 TMOD1 tropomodulin 1 391
48 MYL1 myosin, light chain 1, alkali; skeletal, fast 368
53 TNNI1 troponin I type 1 (skeletal, slow) 356
62 MYH4 myosin, heavy chain 4, skeletal muscle 332
67 UTRN utrophin 325
72 TNNC2 troponin C type 2 (fast) 304
81 SRF serum response factor (c-fos serum response element-binding transcription factor) 278
Congenital muscular dystrophies
Rank Gene Name Score
36 GCNT4 glucosaminyl (N-acetyl) transferase 4, core 2 458
44 GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1
(GalNAc-T1)
444
47 ST8SIA2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 444
51 OGT O-linked N-acetylglucosamine (GlcNAc) transferase 444
53 GALNT2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2
(GalNAc-T2)
444
55 SDF2 stromal cell-derived factor 2 443
57 ST8SIA6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6 442
62 MGAT1 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase 426
Congenital myopathies
Rank Gene Name Score
17 MYH4 myosin, heavy chain 4, skeletal muscle 755
29 MYL1 myosin, light chain 1, alkali; skeletal, fast 640
31 TNNI1 troponin I type 1 (skeletal, slow) 634
37 RYR3 ryanodine receptor 3 587
38 TMOD1 tropomodulin 1 570
43 TNNC2 troponin C type 2 (fast) 527
51 MYH1 myosin, heavy chain 1, skeletal muscle, adult 458
58 MYL6B myosin, light chain 6B, alkali, smooth muscle and non-muscle 438
Metabolic myopathies
Rank Gene Name Score
10 PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit 672
18 PPP1R3C protein phosphatase 1, regulatory subunit 3C 593
21 MTOR mechanistic target of rapamycin (serine/threonine kinase) 588
26 PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic subunit 560
39 ACACB acetyl-CoA carboxylase beta 470
40 PHKG1 phosphorylase kinase, gamma 1 (muscle) 470
44 PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 459
48 GSK3A glycogen synthase kinase 3 alpha 441
Congenital myasthenic syndromes
Rank Gene Name Score
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Table 4. Cont.
Muscular dystrophies
Rank Gene Name Score
11 CHRNB4 cholinergic receptor, nicotinic, beta 4 (neuronal) 817
15 CHRNA6 cholinergic receptor, nicotinic, alpha 6 (neuronal) 680
19 CHRNB3 cholinergic receptor, nicotinic, beta 3 (neuronal) 636
21 CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 628
22 CHRNA9 cholinergic receptor, nicotinic, alpha 9 (neuronal) 616
40 ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 441
52 CHRNA10 cholinergic receptor, nicotinic, alpha 10 (neuronal) 413
61 HTR3B 5-hydroxytryptamine (serotonin) receptor 3B, ionotropic 399
Ion channel muscle diseases
Rank Gene Name Score
12 SCN3A sodium channel, voltage-gated, type III, alpha subunit 1416
13 CACNB1 calcium channel, voltage-dependent, beta 1 subunit 1378
40 RYR3 ryanodine receptor 3 1019
52 CACNG1 calcium channel, voltage-dependent, gamma subunit 1 936
55 CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 930
63 CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta subunit 3 915
70 KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5 888
71 KCNA7 potassium voltage-gated channel, shaker-related subfamily, member 7 888
Myotonic syndromes
Rank Gene Name Score
7 CASQ1 calsequestrin 1 (fast-twitch, skeletal muscle) 1079
8 RYR3 ryanodine receptor 3 954
15 JPH1 junctophilin 1 806
21 MYL1 myosin, light chain 1, alkali; skeletal, fast 703
26 CAMK2D calcium/calmodulin-dependent protein kinase II delta 658
32 SYPL2 synaptophysin-like 2 611
34 ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 610
47 MYH4 myosin, heavy chain 4, skeletal muscle 559
Myofibrillar myopathies
Rank Gene Name Score
27 MYL1 myosin, light chain 1, alkali; skeletal, fast 984
33 MYH4 myosin, heavy chain 4, skeletal muscle 924
35 MYL12B myosin, light chain 12B, regulatory 921
41 TNNI1 troponin I type 1 (skeletal, slow) 909
42 TNNC2 troponin C type 2 (fast) 909
50 PDLIM3 PDZ and LIM domain 3 862
51 MYO18B myosin XVIIIB 845
52 PDLIM5 PDZ and LIM domain 5 844
Vacuolar myopathies
Rank Gene Name Score
4 CD63 CD63 molecule 1160
8 AP1G1 adaptor-related protein complex 1, gamma 1 subunit 1006
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and treatment effects in myopathies [39]. OBSCN encodes
obscurin, a giant sarcomeric signaling protein similar to titin,
which has a suspected role in myofibrillogenesis. It is also involved
in dystrophin localization and maintenance of sarcolemma
integrity [40], and is proposed here as a candidate for congenital
muscular dystrophy with merosin deficiency (MDC1B). An
additional candidate gene mapped in the linked region is
GALNT2, a glycosylating enzyme similar to B3GALNT2 recently
found mutated in another form of congenital muscular dystrophy
[18], and also involved in the O-glycosylation of peptides in the
Golgi apparatus.
Although not directly analyzed in this work, malignant
hyperthermia susceptibility regions encompass CACNG1 and
CACNA2D1, which are associated with calcium homeostasis
and calcium channels, are highly ranked for Ion Channel Muscle
Diseases, and are thus interesting candidates. CACNA2D1,
specifically, has been suggested at least as a modifier of
hyperthermia susceptibility in association to other genes [41].
These genes have been excluded in a limited number of families
not linked to RYR1 mutations [42], results which may be revisited
with the advent of NGS data. Additionally, another candidate
gene, CACNB1, has no associated human disease. However,
CACNG1, CACNB1 and CACNA2D1 encode for subunits of the
DHPR calcium channel, which is in direct contact and regulating
RYR1 in skeletal muscle, and one mutation in the channel subunit
CACNA1S of DHPR was linked to malignant hyperthermia [43].
The CALR and AP1M1 genes both map to 19q13, the locus
associated to autosomal muscular dystrophy with rimmed vacu-
oles. In a recent work, the product of the CALR gene, calreticulin,
has been shown to localize in cardiomyocyte mitochondria, and its
content increases in mouse models with dilated cardiomyopathy
[44]. Strikingly, calreticulin was found to be highly expressed in
GNE myopathy, a distal myopathy associated with rimmed
vacuoles [45]. Also in distal myopathies with rimmed vacuoles,
though not necessarily GNE myopathy, adaptin related-proteins
subunits, which are normally not marked in the immunohisto-
chemistry of normal muscle, appear inside or on the rims of
vacuoles. The AP1M1 gene codes for the mu subunit of adaptin
related-proteins [46].
Discussion
In this study, an integrated data mining strategy was used to
cluster and rank genes with known or potential importance for
skeletal muscle, and to provide candidate genes for myopathies
and some related diseases. Results from the clustering and ranking
highlight pathological pathways specific for disease groups. The list
of candidate genes was further filtered based on expression data
and association with other diseases, and the ensuing identification
of mutations in high-ranked genes for congenital muscular
dystrophies (B3GALNT2, GMPPB and B3GNT1) illustrated the
validity of this approach.
Gene clustering and ranking are dependent on database
annotations
Proposed genes in the final ranked list have gene scores with a
major contribution of GO and IA terms, and eventual contribu-
tion of MPO terms. Thus, they represent genes that have mostly
functional links with known myopathy genes (IA terms and GO
term ontologies for biological processes and molecular functions),
but also some degree of product colocalization in the muscle cell,
as expected from matching cellular component-related GO terms.
When available, data on altered skeletal muscle function in mouse
models also tend to contribute to higher scores for proposed
candidate genes.
Database annotation can vary from one gene to another, as it is
dependent on the history of research for each gene, including both
the date when the gene was discovered and the amount of effort
spent for its functional characterization. In addition, animal
models are generally phenotyped with a specific organ system in
mind.
To illustrate the effects of incomplete annotation, the genes
TRAPPC11 and TNPO3, recently implicated in muscular
dystrophies, were used as components of this disease group
training set, but did not impact the results of the gene ranking due
to their poor database annotation. Likewise, they were themselves
not captured by the signature used for the Muscular Dystrophies
disease group. TRAPPC11 does not appear in the ranking, as it
was annotated with only two GO terms that are not significant for
muscular dystrophies ("vesicle-mediated transport" and "Golgi
apparatus"), it has no annotation for pathways or phenotypes, and
its two protein motifs are unique in the genome. Annotation biases
also account for higher placements of better-annotated genes that
have some kind of overlap with myopathy genes. Such is the case
for motor neuron disease-associated genes, which give rise to
human and mouse phenotypes that present some degree of
phenotypic overlap with myopathies and tend to share many HPO
or MPO terms with myopathy phenotypes. In the ranked list of
muscular dystrophies, high scores with a predominant contribu-
tion of HPO terms were given to the genes SMN1, SMN2, ALS2,
IGHMBP2 and AR. These genes are linked to different types of
motor neuron disease, which ultimately manifest with muscle
weakness and atrophy.
Table 4. Cont.
Muscular dystrophies
Rank Gene Name Score
18 VAMP7 vesicle-associated membrane protein 7 1006
20 MARCH8 membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase 1006
22 ZNRF1 zinc and ring finger 1, E3 ubiquitin protein ligase 1006
26 AP1M1 adaptor-related protein complex 1, mu 1 subunit 1006
27 AP1B1 adaptor-related protein complex 1, beta 1 subunit 1006
40 ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 817
Candidate genes are not associated with disease (as per annotation in OMIM) and are expressed in skeletal muscle with at least 10% of the maximum expression in any
tissue, except for congenital myasthenic syndromes, where there was no expression filtering.
doi:10.1371/journal.pone.0110888.t004
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In silico approaches need thus periodic revisits to adjust
candidate lists based on association of new genes that impact
training sets and discovery of new pathways or interactions that
change corresponding database annotation, such as the recently
published interactome of skeletal muscle proteins centered on
proteins that cause limb-girdle muscular dystrophies [47].
Possible insights into pathological mechanisms
The integrated data mining identified gene signatures revealing
common function within specific myopathy groups or between
groups, and highlighting pathological mechanisms.
Known and candidate genes for metabolic myopathies,
congenital myasthenic syndromes, myotonic syndromes, and ion
channel muscle diseases define distinctive functions for each
disease group (Table 2). Highly ranked genes for congenital
myasthenic syndromes are associated to function not primarily
linked to skeletal muscle but point as expected to the neuromus-
cular junction. The cellular basis of myotonic myopathies and ion
channel muscle diseases consists in the alteration of ion
homeostasis. Additional genes contributing to glycogen metabo-
lism were identified as good candidate genes for the metabolic
myopathies.
Muscle development, muscle contraction and calcium homeo-
stasis are key pathways linked to congenital myopathies; indeed
this myopathy group presents generally at or before birth, and is
characterized by histological hallmarks reflecting alteration and
aggregation of proteins implicated in muscle contraction (nemaline
myopathies) or due to primary defects in the excitation-contraction
coupling (core myopathies and potentially the centronuclear
myopathies).
Muscular dystrophies mainly involve muscle intracellular
organization terms that reflect the structural importance of most
proteins already reported mutated. However, other pathways may
have been overlooked because the way the first genes were
discovered; once the DMD gene was found, investigators started
seeking mutations on genes from the dystrophin-glycoprotein
complex. Of note, based on the terms breakdown and candidate
genes identified, muscular dystrophies may have a larger
contribution from the contractile apparatus than previously
assumed, which would bring this disease group closer to congenital
myopathies.
Allelic diseases
The integrated data mining reveals or confirms allelic diseases.
Indeed, while proposed genes for metabolic myopathies or
myasthenic syndromes are rather group-specific, a larger overlap
occurred between congenital myopathies and muscular dystro-
phies than what was expected from the analysis of overlap between
these groups’ training sets. While only 2 genes out of 34 muscular
dystrophy training set genes also appeared among the 22
congenital myopathy training set genes (TTN and TRIM32), the
first positions on the ranked lists of candidate genes after filtering
for known diseases encompass a large overlap of genes: 5 out of the
top 8 candidate genes for muscular dystrophies are within the top
8 for congenital myopathies (Table 4), and 33 out of the top 50
candidate muscular dystrophy genes are also within the top 50
candidate genes for congenital myopathies (Figure 3 and Table
S2). Overlaps are also substantial between both these lists and the
one for myofibrillar myopathies, but in this case the overlap was
expected as the training set for myofibrillar myopathies, despite
being small (7 genes), included 2 genes also associated to muscular
dystrophies and 1 gene associated to congenital myopathies. On
the other hand, while the training sets of muscular dystrophies and
congenital muscular dystrophies overlap with a significant share of
8 genes, only 3 genes within the top 50 candidate genes is the same
for both groups. The reasons for these results lie in the signature of
the disease groups: the breakdown of biological processes terms
(depicted in Table 2), which represent the larger share of GO
terms, is more comparable between congenital myopathies and
muscular dystrophies, with similar contributions of terms involving
muscle contraction and development, as opposed to the absence of
resemblance between these disease groups and the congenital
muscular dystrophies breakdown, which is enriched with mainly
non-skeletal muscle-related terms, especially glycosylation. Taken
together, gene clustering and candidate genes retrieval suggest that
mutations in the same genes will eventually be linked to both
muscular dystrophies and congenital myopathies.
Table 4 presents the top 8 ranked genes after excluding genes
with known disease annotation. Genes with known disease
annotation (listed in Table S2) might still be good candidate
genes for myopathies, considering that phenotypic variability is
more a rule than an exception for known myopathy genes. This is
the case for genes linked to both myopathy and cardiomyopathy.
It is thus expected that known cardiomyopathy-associated genes
may be found associated with a skeletal muscle phenotype. Such
phenotypic variability may even transcend the realm of muscle
alteration. DNM2, for example, is associated both with centro-
nuclear myopathy, a congenital myopathy, and Charcot-Marie
Tooth disease, a hereditary neuropathy [48,49]. LMNA, in
addition to multiple myopathic phenotypes, also causes Charcot-
Marie Tooth disease or progeria [50,51], and SYNE1 can cause
one type of Emery-Dreifuss muscular dystrophy, a dilated
cardiomyopathy syndrome, a form of autosomal recessive
arthrogryposis, and autosomal recessive spinocerebellar ataxia
Table 5. Candidate genes within genomic regions linked to myopathies and related diseases.
Linked
region
Phenotypes and asssociated disease symbols Candidate genes
1q42 Congenital muscular dystrophy with merosin
deficiency - MDC1B
OBSCN, GALNT2
3p22.2-p21.32 Hyalin body myopathy - HBM XIRP1
3p23-21 Congenital muscle dystrophy with joint hyperlaxity XIRP1
7q21-q22 Malignant hyperthermia susceptibility 3 - MHS3 CACNA2D1
17q11.2-q24 Malignant hyperthermia susceptibility 2 - MHS2 SDF2, SYNRG, CACNB1, CACNG1
19p13 Muscular dystrophy, autosomal dominant,
with rimmed vacuoles - MDRV
CALR, PRKACA, AP1M1
doi:10.1371/journal.pone.0110888.t005
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[52–55]. The origin of the variability may stem from varying
impacts of mutations in different protein domains. For example, in
DNM2, mutations giving rise to a centronuclear myopathy
phenotype are enriched in the interface between the middle
domain and the pleckstrin homology domain, while mutations
implicated in Charcot-Marie-Tooth disease tend to cluster in other
parts of the pleckstrin homology domain [56].
After we carried out this work, a form of vacuolar myopathy was
associated to CLN3, implicated in neuronal ceroid lipofuscinosis,
ranked 343rd for vacuolar myopathies [57]. In addition, LRP4, a
gene associated with Cenani-Lenz syndactyly syndrome and
sclerosteosis, and ranked high (54th) for congenital muscular
dystrophies, was implicated in a patient with a CMS disease [58].
We therefore suggest that genes with disease annotation in the
ranked lists should be considered with caution in analyzing NGS
results, but not a priori excluded when using filtering pipelines.
Example of the usage of the ranked lists
We found the ranked lists to be helpful in our own analysis of
exome data to prioritize the scrutiny of potential novel genes
implicated in myopathies. The gene ranks in the Excel file sheets
in Table S2 can be easily used as additional genomic annotation.
Consider this exome of a sporadic patient affected with
nemaline myopathy, a congenital myopathy, from unaffected
parents (Table S4). Out of an initial 86,333 variants called in the
exome data, 250 remained after variants filtering to exclude
purported sequencing errors and polymorphisms. The first
variants we analyze closely are the ones found in genes with
known implication in myopathies. The heterozygous variants in
DMD and CACNA1S were subsequently found in the unaffected
father, while the missense variant in ANO5, associated with
autosomal recessive limb girdle dystrophy 2L, would require an
association to a second mutation to cause disease. We can thus
exclude the implication of these known genes.
We next focus on the candidate genes for congenital myopathies
(Table 4 and Table S2). If a gene has more than 10% expression
in skeletal muscle and is not associated to a disease, it receives a
flag as a ‘‘candidate’’. Only 29 variants, a significant reduction
from the original 250, survive this additional filtering and are
shown in Table 6.
The gene with the highest rank was PXN, which codes for
paxillin, a protein believed to have a function related to integrins
and cytoskeletal localization in multiple tissues, skeletal muscle
included [59]. The second best gene was MYBPH, which codes
for myosin-binding protein H, the second most abundant protein
of the family of myosin-associated proteins [60]. Except for its
cloning, not much is known about its specific function. The third
gene, PPARGC1A, has regulatory functions on glucose and fat
oxidation in muscle cells and protects skeletal muscle fibers against
atrophy in mouse models [61]. However, in all these genes, single
mutations were found in a heterozygous state, thus a putative
dominant negative effect or haploinsufficiency would be required
for a pathogenicity call. The next gene in the list, SYNPO,
produces synaptopodin, a protein whose name stems from its
involvement in synapses involving dendritic spines, in addition to
renal podocytes [62]. In spite of its name, skeletal muscle is
actually the tissue where it is most strongly expressed. Further-
more, synaptopodin directly binds actin, one of the proteins
known to be involved in nemaline myopathy. The missense variant
found in this gene was homozygous, in a highly evolutionary
conserved position, with prediction of pathogenicity in multiple
tools, and was Sanger confirmed to be homozygous in the patient
and heterozygous in her parents. We believe SYNPO is the best
candidate gene for this family, based on a recessive scenario. While
we cannot discard the other genes, the ranking of candidate genes
based on our integrative data mining quickly highlights the best
genes to proceed further in functional analysis.
Conclusions
The above integrated data mining approach was successfully
used to retrieve both specific signatures for different myopathy
groups and to uncover and rank interesting candidate genes for
myopathies. Recent discoveries of gene implications that were
Figure 3. Venn diagrams of gene set overlaps. A: Venn diagram showing the overlap of training set genes between muscular dystrophies (MD),
congenital myopathies (CM) and congenital muscular dystrophies (CMD). B: Venn diagram showing the overlap of genes found within the top 50
ranked candidate genes in the three disease groups.
doi:10.1371/journal.pone.0110888.g003
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correctly identified by the disease group’s signature validated this
approach. In silico approaches allow for systematic, but modifiable
criteria to be used in generating ranked candidate lists and have
the added benefit of automation, whereby such lists can be
updated on the fly as new knowledge is incorporated in genomic
databases.
Signatures and candidate genes highlighted both potential
common pathological mechanisms and overlap between several
disease groups. In addition, the ranked candidate gene lists are
helpful to prioritize functional validation of filtered variants from
overwhelming NGS data.
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Table 6. Resulting 29 variants after filtration of exome data of a patient affected with nemaline myopathy.
CM Rank Flag VariantID State Gene Spec%
208 candidate 12_120660719_C_T Heterozygous PXN 22
355 candidate 1_203139425_T_A Heterozygous MYBPH 16
446 candidate 4_23803919_C_T Heterozygous PPARGC1A 30
586 candidate 5_150028613_T_C Homozygous SYNPO 100
610 candidate 5_138160333_G_A Heterozygous CTNNA1 34
786 candidate 10_115374035_A_T Heterozygous NRAP 100
856 candidate 1_87208087_A_G Heterozygous SH3GLB1 100
951 candidate 6_36076169_A_G Heterozygous MAPK14 18
1044 candidate 11_1901435_C_T Heterozygous LSP1 36
1044 candidate 11_1901435_C_T Heterozygous LSP1 36
1199 candidate 9_125863896_C_T Heterozygous RABGAP1 38
1758 candidate 12_95604081_G_A Heterozygous FGD6 17
1902 candidate 14_103420979_G_A Heterozygous CDC42BPB 32
1976 candidate 9_124522285_C_T Heterozygous DAB2IP 43
2066 candidate 22_19865895_A_C Heterozygous TXNRD2 16
2231 candidate 5_95116054_A_T Heterozygous RHOBTB3 32
2245 candidate 22_41652800_A_C Heterozygous RANGAP1 25
2263 candidate 2_159477732_C_A Heterozygous PKP4 10
2360 candidate 2_152980460_G_T Heterozygous STAM2 26
2679 candidate 1_46472006_A_G Heterozygous MAST2 100
3075 candidate 10_68138967_C_T Heterozygous CTNNA3 19
3434 candidate 7_156976610_G_A Heterozygous UBE3C 100
3530 candidate 9_32407367_C_T Heterozygous ACO1 16
3627 candidate 1_19453077_C_T Heterozygous UBR4 100
4029 candidate 20_35632140_C_G Heterozygous RBL1 40
4235 candidate 22_50356432_A_T Heterozygous PIM3 47
4375 candidate 11_75115893_C_A Heterozygous RPS3 14
5062 candidate 1_204494668_G_A Heterozygous MDM4 47
5084 candidate 7_21469915_C_T Heterozygous SP4 36
An initial 86,333 variants were reduced to 250 using criteria on the variant level, which resulted in the 29 variants after exclusion of genes already ascribed to diseases
and based on specificity of skeletal muscle expression. Variants are then sorted according to the gene ranking calculated for the congenital myopathy group.
doi:10.1371/journal.pone.0110888.t006
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